Governance
New Members Elected to ÐǺ£ÆåÅÆ’s Board of Directors
21 March 2025
Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Research
Innovation
Discover how ÐǺ£ÆåÅÆ makes a positive impact for patients, communities, employees and the environment
Corporate and financial resources for ÐǺ£ÆåÅÆ investors, potential shareholders and analysts
Resources
Financials
Stock Information
Governance
News
News & Insights
When you have a passion for innovation and an aspiration to improve the lives of patients with cancer and other serious diseases, you are going to make some headlines. Learn about our latest news below.
Latest news
Apr 28, 2025 at 02:16 PM CEST
Transactions in Connection with Share Buy-back Program
Apr 22, 2025 at 01:23 PM CEST
Transactions in Connection with Share Buy-back Program
Apr 15, 2025 at 12:22 PM CEST
ÐǺ£ÆåÅÆ Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Apr 28, 2025 at 02:16 PM CEST
Transactions in Connection with Share Buy-back Program
Apr 22, 2025 at 01:23 PM CEST
Transactions in Connection with Share Buy-back Program
Apr 15, 2025 at 12:22 PM CEST
ÐǺ£ÆåÅÆ Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Featured Stories
Explore our media library so you can put faces to names, see our state-of-the-art offices and get to know our cutting-edge research center.
Press contacts
Reach out to the ÐǺ£ÆåÅÆ team for more information.
Marisol Peron
Senior Vice President, Communications and Corporate Affairs
For general Investor Relations Inquiries please contact ir@genmab.com.
Andrew Carlsen
Vice President, Head of Investor Relations
For general Investor Relations Inquiries please contact ir@genmab.com.